Tigecycline was approved in June 2005 by the FDA for the treatment of cSSIs and cIAIs in adult patients. Since that time, the drug has also been approved in many South American countries, including Argentina, Brazil and Colombia. In May 2006, the European Commission also granted its approval of tigecycline for use in cSSIs and cIAIs.
Expert Rev Anti Infect Ther. 2008;6(5):557-567. © 2008 Expert Reviews Ltd.
No writing assistance was utilized in the production of this manuscript.
Cite this: Establishing the Role of Tigecycline in an era of Antimicrobial Resistance - Medscape - Oct 01, 2008.